All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb and Incyte. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View MPN content recommended for you
Impact of treatment on thrombotic complications in AYA with ET and PV: A retrospective analysis
ET and PV are linked with thrombotic complications in older patients. However, data are limited in AYA patients. A retrospective analysis evaluating the impact of treatment on thrombotic risk and secondary MF progression in AYA with ET and PV was published by Beauverd et al. in Leukemia.1 The cohort included 278 AYA patients with ET and 70 patients with PV. The primary outcomes were TFS and MFS. Secondary outcomes included risk factors associated with thrombotic events and secondary MF.
|
| Key learnings |
The estimated 10- and 20-year TFS rates were 86.8% and 78.8% for the entire cohort, 86.9% and 80.0% for the ET cohort, and 84.4% and 76.3% for the PV cohort, respectively. |
The 10- and 20-year MFS rates were 95.2% and 81.3% for the entire cohort, 94.7% and 75.7% for the ET cohort, and 96.8% and 93.3% for the PV cohort, respectively. |
CALR mutation (HR, 6.0; 95% CI, 2.3–16.1; p < 0.001) and thrombosis history (HR, 3.8; 95% CI, 1.3–11.4; p = 0.015) at diagnosis were associated with increased risk of secondary MF progression. |
Elevated WBC count (HR, 2.7; 95% CI, 1.2–6.0; p = 0.012) and absence of splenomegaly at diagnosis (HR, 5.7; 95% CI, 1.2–26.0; p = 0.026) were associated with increased risk of thrombosis. |
Treatment with IFN was associated with a lower risk of secondary MF progression compared with HU, ANA, or the absence of cytoreduction (p = 0.046). |
The analysis suggests that AYA patients have similar rates of thrombosis and secondary MF to those of older patients. AYA patients treated with IFN showed no disease progression, supporting its potential as a first-line treatment in this younger population. |
Abbreviations: ANA, anagrelide; AYA, adolescent and young adult; CALR, calreticulin mutation; CI, confidence interval; ET, essential thrombocythemia; HR, hazard ratio; HU, hydroxycarbamide; IFN, interferon; MF, myelofibrosis; MFS, myelofibrosis-free survival; PV, polycythemia vera; TFS, thrombosis-free survival; WBC, white blood cell.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
